Get ready to move over, Sanofi. A slew of Big Pharma rivals are reportedly weighing their own bids for buyout target Medivation.
Novartis, Pfizer and AstraZeneca are all exploring pitching a counteroffer for the San Francisco drugmaker, which Friday rejected a $9.3 billion buyout bid from the French pharma giant, Bloomberg reports. The trio is conferring with advisers about Medivation’s value, and whether and how to move forward, though there’s no guarantee they’ll come through with their own proposals.
Astellas, which markets star Medivation cancer drug Xtandi, could also jump into the mix, analysts have predicted.
Of course, Sanofi–which saw its $52.50-per-share bid snubbed–could always raise its offer. Still, despite its desire to boost its oncology portfolio, the French drugmaker is wary of overpaying, Bloomberg’s sources say. Medivation–which said the bid substantially undervalued its business–is looking for bids of at least $65 per share, the news service reports, and analysts including Leerink Partners’ Geoffrey Porges and Canaccord Genuity’s David Evanson have estimated value as high as $70.
It’s no surprise multiple drugmakers are giving Medivation a look, considering how many companies have stated a desire to expand in oncology. After last year snagging GlaxoSmithKline’s cancer drugs in a multibillion-dollar asset swap, Novartis has a big focus on the field, and Pfizer could once again be looking to bulk up its three operating units in the wake of its canceled deal with Allergan.
Meanwhile, AstraZeneca has been looking to the cancer arena to help spark the revenue turnaround CEO Pascal Soriot has been promising.
Xtandi could help any of them toward achieving their goals. The prostate cancer therapy’s sales–shared with Astellas–rang up at $1.9 billion worldwide last year, and analysts predict the med will eventually overtake first-to-market competitor pill Zytiga from Johnson & Johnson.
By Carly Helfand
Source: Fierce Pharma
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.
